Literature DB >> 3495778

Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis.

M Martea, Y A Hekster, T B Vree, A J Voets, J H Berden.   

Abstract

Cefradine and co-trimoxazole pharmacokinetics were studied in a patient with peritonitis that complicated continuous ambulatory peritoneal dialysis (CAPD). Concentrations in the plasma reached after oral administration of 500 mg cefradine four times daily and 400/80 mg co-trimoxazole four times daily were for cefradine 100 micrograms/ml, for trimethoprim 15 micrograms/ml, and for sulfamethoxazole 100 micrograms/ml, respectively. In the dialysate concentrations were reached of 35-70 micrograms/ml cefradine, 2-5 micrograms/ml trimethoprim and 8-17 micrograms/ml sulfamethoxazole. The values for sulfamethoxazole are regarded too low to be clinically effective. Half-lives, protein binding values and CAPD clearances are presented. Low CAPD clearances were obtained during the night and high values during the day. The dosage yielded too high plasma trimethoprim concentrations, while sulfamethoxazole dialysate concentrations were too low. It seems questionable therefore whether co-trimoxazole can be used orally for the treatment of CAPD peritonitis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495778     DOI: 10.1007/BF01960745

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  20 in total

1.  Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis.

Authors:  Y A Hekster; T B Vree; C M Weemaes; J J Rotteveel
Journal:  Pharm Weekbl Sci       Date:  1986-12-12

2.  Pharmacokinetics of N1-acetyl- and N4-acetylsulphamethoxazole in man.

Authors:  T B Vree; Y A Hekster; J E Damsma; E van der Kleijn; W J O'Reilly
Journal:  Clin Pharmacokinet       Date:  1979 Jul-Aug       Impact factor: 6.447

3.  Dosage adjustment for ceftazidime in patients with impaired renal function.

Authors:  R van Dalen; T B Vree; A M Baars; E Termond
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Peritonitis during continuous ambulatory peritoneal dialysis.

Authors:  J Rubin; W A Rogers; H M Taylor; E D Everett; B F Prowant; L V Fruto; K D Nolph
Journal:  Ann Intern Med       Date:  1980-01       Impact factor: 25.391

5.  Oral treatment of peritonitis complicating continuous ambulatory peritoneal dialysis.

Authors:  M Searle; G V Raman
Journal:  Clin Nephrol       Date:  1985-05       Impact factor: 0.975

6.  Treatment of peritonitis in continuous ambulatory peritoneal dialysis patients with co-trimoxazole.

Authors:  P Glasson; H Favre
Journal:  Nephron       Date:  1984       Impact factor: 2.847

7.  Deterioration of kidney function by high doses of co-trimoxazole in man.

Authors:  T B Vree; M Martea; Y A Hekster; E F Termond; R Van Klaveren; J W Lammers; J H Berden
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

8.  Controversies in antimicrobial therapy: innovative methods of administration.

Authors:  L H Danziger
Journal:  Am J Hosp Pharm       Date:  1986-03

9.  Some consequences of drug choice and dosage regimen for patients with impaired kidney function.

Authors:  T B Vree; C A Hekster; R van Dalen
Journal:  Drug Intell Clin Pharm       Date:  1983-04

10.  In vitro antimicrobial activity of hydroxy and N4-acetyl sulphonamide metabolites.

Authors:  J F Nouws; T B Vree; Y A Hekster
Journal:  Vet Q       Date:  1985-01       Impact factor: 3.320

View more
  6 in total

Review 1.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Co-trimoxazole (sulphamethoxazole plus trimethoprim) peritoneal barrier transfer pharmacokinetics.

Authors:  J E Svirbely; A J Pesce; S Singh; E J O'Flaherty
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

3.  Pharmacokinetics of theophylline and its metabolites in a patient undergoing continuous ambulatory peritoneal dialysis.

Authors:  T B Vree; M Martea; R G Tiggeler; Y A Hekster; J C Hafkenscheid
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

5.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

6.  Pharmacokinetics of methotrexate in continuous ambulatory peritoneal dialysis.

Authors:  R Janknegt; M J Nube; H M Van den Hoogenband; H G Oldenhof; A Steenhoek; T B Vree
Journal:  Pharm Weekbl Sci       Date:  1988-04-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.